Most Read Articles
3 days ago
Tetanus toxoid 5 Lf, diphtheria toxoid 2 Lf, pertussis toxoid 2.5 mcg, filamentous haemagglutinin 5 mcg, fimbriae types 2 and 3 5 mcg, pertactin 3 mcg
Pearl Toh, 22 Oct 2020
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
Jairia Dela Cruz, 3 days ago
The selective serotonin reuptake inhibitor escitalopram holds promise in the prevention of Alzheimer’s disease, reducing amyloid-β-42 levels in cerebrospinal fluid and brain tissue in older adults with normal cognitive function, according to recent evidence.
Roshini Claire Anthony, 13 Nov 2020

Diabetes is a key risk factor for heart failure (HF), which is the leading cause of hospitalization in patients with or without diabetes. SGLT-2* inhibitors (SGLT-2is) have been shown to reduce the risk of hospitalization for HF (HHF) regardless of the presence or absence of diabetes.

Tipifarnib shows promise in refractory HRAS-mutant urothelial carcinoma

27 Oct 2020

Treatment with tipifarnib appears to be safe with favourable efficacy in patients with treatment-refractory urothelial carcinoma harbouring HRAS mutations, according to the results of a phase II trial.

In total, 21 adult patients (median age, 64 years) with mutated advanced urothelial carcinoma received oral tipifarnib 900 mg twice daily on days 1–7 and 15–21 of 28-day treatment cycles. The patients had received a median of two prior systemic chemotherapy, with two of them having been exposed to immune checkpoint inhibitors (SMC-15 and -20).

Of the patients, 14 had missense HRAS mutations and seven were STK11:rs2075606 carriers. Four patients (19 percent) achieved the primary endpoint of progression-free survival (PFS) at 6 months: three with missense HRAS mutations and one who was an STK11 carrier had HRAS frameshift insertions at H27fs and H28fs, which rendered a nonsense HRAS mutation.

The overall response rate was 24 percent (four patients with missense and one patient with nonsense frameshift HRAS mutation). Tipifarnib did not produce a response in any of the patients with wild-type HRAS tumours.

Over a median follow-up of 28 months, the median PFS was 4.7 months (95 percent confidence interval [CI], 2.5–5.6) while the median overall survival was 6.1 months (95 percent CI, 5.0–7.2).

A total of 97 tipifarnib cycles (median, 3; range, 1 to 18) were delivered. At the final analysis, only two patients remained on treatment. The most frequent reason for discontinuation was disease progression (n=14).

All patients developed a treatment-related adverse event (TRAE), with 14 (67 percent) experiencing higher-grade TRAE. Commonly reported adverse events included fatigue (86 percent) and haematologic toxicities.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
3 days ago
Tetanus toxoid 5 Lf, diphtheria toxoid 2 Lf, pertussis toxoid 2.5 mcg, filamentous haemagglutinin 5 mcg, fimbriae types 2 and 3 5 mcg, pertactin 3 mcg
Pearl Toh, 22 Oct 2020
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
Jairia Dela Cruz, 3 days ago
The selective serotonin reuptake inhibitor escitalopram holds promise in the prevention of Alzheimer’s disease, reducing amyloid-β-42 levels in cerebrospinal fluid and brain tissue in older adults with normal cognitive function, according to recent evidence.
Roshini Claire Anthony, 13 Nov 2020

Diabetes is a key risk factor for heart failure (HF), which is the leading cause of hospitalization in patients with or without diabetes. SGLT-2* inhibitors (SGLT-2is) have been shown to reduce the risk of hospitalization for HF (HHF) regardless of the presence or absence of diabetes.